Viridian Therapeutics, Inc.\DE Quarterly Share-based Payment Arrangement, Expense in USD from Q2 2014 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Viridian Therapeutics, Inc.\DE quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q2 2014 to Q3 2024.
  • Viridian Therapeutics, Inc.\DE Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $8.72M, a 35.9% decline year-over-year.
  • Viridian Therapeutics, Inc.\DE Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $59.2M, a 27.6% increase year-over-year.
  • Viridian Therapeutics, Inc.\DE annual Share-based Payment Arrangement, Expense for 2023 was $67.2M, a 240% increase from 2022.
  • Viridian Therapeutics, Inc.\DE annual Share-based Payment Arrangement, Expense for 2022 was $19.8M, a 36.6% increase from 2021.
  • Viridian Therapeutics, Inc.\DE annual Share-based Payment Arrangement, Expense for 2021 was $14.5M, a 297% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $59.2M $8.72M -$4.89M -35.9% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 $64.1M $11.8M -$535K -4.35% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $64.6M $12.7M -$2.53M -16.6% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $67.2M $26M +$20.8M +394% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-27
Q3 2023 $46.4M $13.6M +$8.66M +175% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 $37.7M $12.3M +$7.42M +152% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $30.3M $15.2M +$10.6M +227% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $19.8M $5.28M +$1.79M +51.2% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-27
Q3 2022 $18M $4.94M +$961K +24.1% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 $17M $4.89M +$1.07M +28% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $15.9M $4.66M +$1.48M +46.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 $14.5M $3.49M +$1.75M +100% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-27
Q3 2021 $12.7M $3.98M +$3.37M +547% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $9.35M $3.82M +$3.19M +513% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 $6.16M $3.18M +$2.51M +378% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-13
Q4 2020 $3.65M $1.74M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-11
Q3 2020 $615K Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-05
Q2 2020 $623K Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 $664K -$354K -34.8% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-07
Q1 2019 $1.02M +$228K +28.9% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-08
Q1 2018 $2.78M $790K +$371K +88.5% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q4 2017 $2.41M $716K +$643K +881% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-14
Q3 2017 $1.77M $679K +$634K +1409% Jul 1, 2017 Sep 30, 2017 10-Q 2017-11-09
Q2 2017 $1.13M $595K +$553K +1317% Apr 1, 2017 Jun 30, 2017 10-Q 2017-08-11
Q1 2017 $579K $419K +$381K +1003% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-09
Q4 2016 $198K $73K -$684K -90.4% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-15
Q3 2016 $882K $45K -$793K -94.6% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-09
Q2 2016 $1.68M $42K -$670K -94.1% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-11
Q1 2016 $2.35M $38K -$670K -94.6% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-11
Q4 2015 $3.02M $757K Oct 1, 2015 Dec 31, 2015 10-K 2017-03-24
Q3 2015 $838K +$135K +19.2% Jul 1, 2015 Sep 30, 2015 10-Q 2016-10-26
Q2 2015 $712K -$2.16M -75.2% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-15
Q1 2015 $708K Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-16
Q3 2014 $703K Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-13
Q2 2014 $2.88M Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.